Irish Family Receives €3.6 Million Settlement in Epilepsy Drug Case
Three children from the same family have been awarded interim settlements totaling €3.6 million following a lawsuit alleging a failure to adequately inform their mother about the risks associated with the epilepsy drug sodium valproate during pregnancy. The settlements, approved by the High Court on March 26, 2026, will cover the children’s needs for the next eight years.
Background of the Case
The legal action centered on claims that the Health Service Executive (HSE) did not sufficiently investigate or communicate the potential risks of prescribing sodium valproate (as well known as Epilim) to the mother during her pregnancies. The children were born in 2011, 2013, and 2015. The family’s counsel, Aongus O’Brolchain, stated that the children have been diagnosed with fetal valproate spectrum disorder, a condition linked to in-utero exposure to the drug, and have also received diagnoses on the autism spectrum.
Mother’s Experience and Allegations
The mother, who developed juvenile absence epilepsy in her late teens, was prescribed sodium valproate to manage her seizures. She was reportedly advised of a 3% risk of complications during pregnancy, with the understanding that folic acid supplementation would mitigate this risk. However, she alleges that the full extent of the risks associated with the medication was not adequately explained to her. The doctor involved in her care maintains that they routinely explained these risks to patients.
Fetal Valproate Spectrum Disorder
Fetal valproate spectrum disorder (FVSD) is a range of neurodevelopmental problems associated with exposure to valproic acid during pregnancy. These problems can include developmental delays, cognitive impairments, and autism spectrum disorder, as seen in the cases of these three children.
Settlement Details and Court Approval
The settlements against the HSE were reached through mediation and do not constitute an admission of liability. Judge Leonie Reynolds approved the interim settlements, describing the outcome as “very good” for the children. The case is scheduled to return to court in eight years to reassess the children’s future care needs.
Implications and Ongoing Concerns
This case highlights the critical importance of fully informing pregnant women, or those planning to become pregnant, about the potential risks and benefits of all medications, particularly those with known teratogenic effects. The alleged failure to adequately assess and communicate these risks raises questions about the standard of care provided to expectant mothers and the potential long-term consequences for children exposed to such medications in utero.